IRD7:00 AMOpus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conferenceopusgtx.com
IRD7:00 AMOpus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate UpdateTrial Results • Phase 1/2OPGx-BEST1 Cohort 1 topline data Tue, Sep 1, 2026, 10:00 AM ETGopusgtx.com
IRD4:30 PMOpus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal DiseasesPresentation / Abstract • Phase 1/2opusgtx.com
IRD7:00 AMOpus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy StudyEnrollment • Phase 1/2opusgtx.com
IRD4:30 PMOpus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Programopusgtx.com
IRD8:00 AMOpus Genetics to Participate in Leading Medical Conferences in May 2026Presentation / Abstract • Phase 1opusgtx.com
IRD6:59 AMOpus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingPresentation / Abstract • Phase 3opusgtx.com
IRD7:00 AMOpus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capitalopusgtx.com
IRD7:00 AMOpus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026opusgtx.com
IRD7:00 AMOpus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate UpdatePresentation / Abstract • Phase 1/2opusgtx.com